Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience

Abstract : We retrospectively evaluated the role of rituximab (R) in maintenance treatment after autologous stem cell transplantation performed in patients with relapsed follicular lymphoma. We compared the outcome of 67 follicular lymphoma (FL) patients according to the use of rituximab maintenance (RM) or not. All patients received rituximab plus chemotherapy before autologous stem-cell transplantation (ASCT). Patients received median of two lines of prior therapy. The RM schedule was one injection of rituximab every 3 months for 2 years. Median follow-up is 4.6 years. The 3-year progression-free survival (PFS) after ASCT was 86 % with RM vs. 46 % without (p = 0.0045). Median is not reached in the RM arm vs. 31 months in non-RM arm. The 3-year OS was 96 % with RM vs. 78 % without (p = 0.059). The present monocentric study shows that 2 years of RM after ASCT significantly increases response duration for non-naive rituximab relapsed FL patients compared with observation.
Type de document :
Article dans une revue
Annals of Hematology, Springer Verlag, 2016, 95, pp.1287-1293. 〈10.1007/s00277-016-2705-z〉
Liste complète des métadonnées

Littérature citée [15 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-01411093
Contributeur : Elizabeth Bernardo <>
Soumis le : mercredi 7 décembre 2016 - 08:28:16
Dernière modification le : jeudi 15 mars 2018 - 14:12:25

Fichier

 Accès restreint
Fichier visible le : jamais

Connectez-vous pour demander l'accès au fichier

Identifiants

Collections

Citation

J. Bourcier, T. Gastinne, C. Leux, A. Moreau, C. Bossard, et al.. Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience. Annals of Hematology, Springer Verlag, 2016, 95, pp.1287-1293. 〈10.1007/s00277-016-2705-z〉. 〈inserm-01411093〉

Partager

Métriques

Consultations de la notice

62